Evolent Health (EVH)
(Real Time Quote from BATS)
$22.65 USD
+0.46 (2.07%)
Updated Jul 26, 2024 09:44 AM ET
4-Sell of 5 4
C Value A Growth A Momentum A VGM
Income Statements
Fiscal Year end for Evolent Health, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,964 | 1,352 | 908 | 1,022 | 846 |
Cost Of Goods | 1,503 | 1,035 | 658 | 701 | 513 |
Gross Profit | 460 | 317 | 250 | 321 | 333 |
Selling & Adminstrative & Depr. & Amort Expenses | 532 | 313 | 293 | 592 | 640 |
Income After Depreciation & Amortization | -71 | 4 | -42 | -271 | -307 |
Non-Operating Income | -77 | -50 | 38 | -39 | -6 |
Interest Expense | 54 | 16 | 25 | 28 | 15 |
Pretax Income | -202 | -62 | -30 | -338 | -327 |
Income Taxes | -89 | -43 | 0 | -4 | -22 |
Minority Interest | 0 | 0 | 0 | 0 | -4 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -113 | -19 | -30 | -334 | -306 |
Extras & Discontinued Operations | 0 | 0 | -7 | 0 | 0 |
Net Income (GAAP) | -113 | -19 | -38 | -334 | -302 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 67 | 96 | 49 | 42 | -31 |
Depreciation & Amortization (Cash Flow) | 138 | 93 | 91 | 313 | 276 |
Income After Depreciation & Amortization | -71 | 4 | -42 | -271 | -307 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 111.25 | 93.70 | 86.07 | 84.93 | 82.36 |
Diluted EPS Before Non-Recurring Items | 0.42 | 0.59 | -0.18 | -0.38 | -0.91 |
Diluted Net EPS (GAAP) | -1.28 | -0.20 | -0.44 | -3.94 | -3.67 |
Fiscal Year end for Evolent Health, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 639.65 | 556.06 | 511.02 | 469.14 |
Cost Of Goods | NA | 535.55 | 454.43 | 386.59 | 351.94 |
Gross Profit | NA | 104.11 | 101.63 | 124.43 | 117.20 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 117.51 | 122.97 | 142.36 | 138.76 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -13.40 | -21.34 | -17.93 | -21.56 |
Non-Operating Income | NA | 2.69 | -14.48 | 1.68 | 0.73 |
Interest Expense | NA | 6.00 | 12.24 | 14.61 | 14.46 |
Pretax Income | NA | -16.72 | -48.07 | -30.87 | -35.29 |
Income Taxes | NA | 0.57 | -14.66 | -5.55 | -0.97 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -17.28 | -33.41 | -25.32 | -34.32 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -17.28 | -33.41 | -25.32 | -34.32 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 114.14 | 113.59 | 112.28 | 111.28 |
Diluted EPS Before Non-Recurring Items | NA | 0.16 | 0.15 | 0.19 | 0.06 |
Diluted Net EPS (GAAP) | NA | -0.22 | -0.37 | -0.30 | -0.37 |